1. [1] Thongsuksai P, Chongsuvivatwong V, Sriplung H. Delay in breast cancer care: a study in Thai women. Med Care 2000; 38: 108-114. [ DOI:10.1097/00005650-200001000-00012] [ PMID] 2. [2] Taslimi Y, Zahedifard F, Habibzadeh S, Taheri T, Abbaspour H, Sadeghipour A, et al. Antitumor effect of IP-10 by using two different approaches: live delivery system and gene therapy. J Breast Cancer 2016; 19: 34-44. [ DOI:10.4048/jbc.2016.19.1.34] [ PMID] [ PMCID] 3. [3] Semnani V, Farhidzadeh E, Mirmohammadkhani M, Ghahremanfard F. Investigation of blood levels of vitamin D in women with breast cancer and its correlation with prognostic markers. Koomesh 2017; 735-741. (Persian). 4. [4] Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 2009; 15: 593-602. [ DOI:10.1111/j.1524-4741.2009.00822.x] [ PMID] 5. [5] Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012; 9: 16-32. [ DOI:10.1038/nrclinonc.2011.177] [ PMID] 6. [6] Ahmadi A, Mohagheghi MA, Fazeli MS, Nahavandian B, Bashardoost N, Jarahi AM, Gharipoor M. HESA-A: new treatment for breast cancer and choroidal metastasis. Med Sci Monit 2005; 11: CR300-CR303. 7. [7] Murphy CG, Modi S. HER2 breast cancer therapies: a review. Biologics 2009; 3: 289-301. [ DOI:10.2147/BTT.S3479] [ PMID] 8. [8] Kauraniemi P, Kallioniemi A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer 2006; 13: 39-49. [ DOI:10.1677/erc.1.01147] [ PMID] 9. [9] Foroumadi S, Rajabi bazl M, Hosseini H, Rajabi S, Shahidi S, Daraei A, Toofani Milani A. Expression and characterization of recombinant human epidermal growth factor receptor antigene (HER-2) as an indicator of breast cancer in yeast fermented systems. Koomesh 2016; 18: 110-116. (Persian). 10. [10] Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010; 146: 264-275. [ DOI:10.1016/j.jconrel.2010.04.009] [ PMID] [ PMCID] 11. [11] Mohit E, Hashemi A, Allahyari M. Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. Expert Rev Clin Immunol 2014; 10: 927-961. [ DOI:10.1586/1744666X.2014.916211] [ PMID] 12. [12] Suárez I, Salmerón-García A, Cabeza J, Capitán-Vallvey LF, Navas N. Development and use of specific ELISA methods for quantifying the biological activity of bevacizumab, cetuximab and trastuzumab in stability studies. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1032: 155-164. [ DOI:10.1016/j.jchromb.2016.05.045] [ PMID] 13. [13] Cheng W, Allen T. The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. Expert Opin Drug Deliv 2010; 7: 461-478. [ DOI:10.1517/17425240903579963] [ PMID] [ PMCID] 14. [14] Damen CW, de Groot ER, Heij M, Boss DS, Schellens JH, Rosing H, et al. Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma. Anal Biochem 2009; 391: 114-120. [ DOI:10.1016/j.ab.2009.05.030] [ PMID] 15. [15] Steinitz M. Quantitation of the blocking effect of tween 20 and bovine serum albumin in ELISA microwells. Anal Biochem 2000; 282: 232-238. [ DOI:10.1006/abio.2000.4602] [ PMID] 16. [16] Sentandreu MA, Aubry L, Toldrá F, Ouali A. Blocking agents for ELISA quantification of compounds coming from bovine muscle crude extracts. Eur Food Res Technol 2007; 224: 623-628. [ DOI:10.1007/s00217-006-0348-3] 17. [17] Khan MS, Pande T, van de Ven TG. Qualitative and quantitative detection of T7 bacteriophages using paper based sandwich ELISA. Colloids Surf B Biointerfaces 2015; 132: 264-270. [ DOI:10.1016/j.colsurfb.2015.05.028] [ PMID] 18. [18] Crowther R. The ELISA Guidebook. ed. Humana Press; 2009; 88-97. [ DOI:10.1007/978-1-60327-254-4] 19. [19] Mosayebi G, Abtahi H, Ghazavi A, Zareinfar N, Khaki M, Payani MA. Design of enzyme-linked immunosorbent assay method for detection of anti-streptolysin-O antibodies on base of recombinant streptolysin-O. Koomesh 2012; 13: 362-368. (Persian). 20. [20] Péterfi Z, Kocsis B. Comparison of blocking agents for an ELISA for LPS. J Immunoassay 2000; 21: 341-354. [ DOI:10.1080/01971520009349541] [ PMID] 21. [21] Coory M, Thornton K. Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review. Breast Cancer Res Treat 2019; 1: 17-25. [ DOI:10.1007/s10549-019-05227-7] [ PMID] 22. [22] Holbech H, Andersen L, Petersen GI, Korsgaard B, Pedersen KL, Bjerregaard P. Development of an ELISA for vitellogenin in whole body homogenate of zebrafish (Danio rerio). Comp Biochem Physiol C Toxicol Pharmacol 2001; 130: 119-131. [ DOI:10.1016/S1532-0456(01)00229-0] 23. [23] Dixit CK, Vashist SK, MacCraith BD, O'kennedy R. Multisubstrate-compatible ELISA procedures for rapid and high-sensitivity immunoassays. Nat Protoc 2011; 6: 439-445. [ DOI:10.1038/nprot.2011.304] [ PMID] 24. [24] Kaur R, Dikshit KL, Raje M. Optimization of immunogold labeling TEM: an ELISA-based method for evaluation of blocking agents for quantitative detection of antigen. J Histochem Cytochem 2002; 50: 863-873. [ DOI:10.1177/002215540205000612] [ PMID] 25. [25] Khodashenas S, Khalili S, Moghadam MF. A cell ELISA based method for exosome detection in diagnostic and therapeutic applications. Biotechnol Lett 2019; 41: 523-531. [ DOI:10.1007/s10529-019-02667-5] [ PMID] 26. [26] Meysami P, Rezaei F, Marashi SM, Amiri MM, Bakker E, Mokhtari-Azad T. Antitumor effects of a recombinant baculovirus displaying anti-HER2 scFv expressing Apoptin in HER2 positive SK-BR-3 breast cancer cells. Future Virol 2019; 14: 139-152. [ DOI:10.2217/fvl-2018-0187] 27. [27] Maple L, Lathrop R, Bozich S, Harman W, Tacey R, Kelley M, Danilkovitch-Miagkova A. Development and validation of ELISA for Herceptin detection in human serum. J Immunol Methods 2004; 295: 169-182. [ DOI:10.1016/j.jim.2004.09.012] [ PMID] 28. [28] Tan WB, Jiang S, Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 2007; 28: 1565-1571. [ DOI:10.1016/j.biomaterials.2006.11.018] [ PMID] 29. [29] Alric C, Hervé-Aubert K, Aubrey N, Melouk S, Lajoie L, Même W, et al. Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes. J Nanobiotechnology 2018; 16: 18. [ DOI:10.1186/s12951-018-0341-6] [ PMID] [ PMCID] 30. [30] Lattrich C, Juhasz-Boess I, Ortmann O, Treeck O. Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor β1. Oncol Rep 2008; 19: 811-817. [ DOI:10.3892/or.19.3.811] [ PMID] 31. [31] Huang R, Wang Q, Zhang X, Zhu J, Sun B. Trastuzumab-cisplatin conjugates for targeted delivery of cisplatin to HER2-overexpressing cancer cells. Biomed Pharmacother 2015; 72: 17-23.
https://doi.org/10.1016/j.biopha.2015.03.004 [ DOI:10.1016/j.jpba.2014.08.019] [ PMID] 32. [32] Sarial S, Sonboli R, Maleknia S, Ashori F, Rezaeiravesh S, Nouri SZ, et al. Development, optimization and validation of a sandwich ELISA for detection of recombinant human factor VII. South Asian J Exper Biol 2015; 5: 26-31.
|